Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells

Full description

Bibliographic Details
Published in:American journal of cardiovascular drugs. - Springer International Publishing, 2001. - 23(2023), 5 vom: 31. Juli, Seite 497-518
Main Author: Xiong, Yilin (Author)
Other Authors: Wang, Yan (Author) Yang, Tao (Author) Luo, Yunmei (Author) Xu, Shangfu (Author) Li, Lisheng (Author)
Format: electronic Article
Language:English
Published: 2023
ISSN:1179-187X
External Sources:lizenzpflichtig
LEADER 01000naa a22002652 4500
001 OLC2145272240
003 DE-627
005 20240118103637.0
007 cr uuu---uuuuu
008 240118s2023 xx |||||o 00| ||eng c
024 7 |a 10.1007/s40256-023-00596-3  |2 doi 
035 |a (DE-627)OLC2145272240 
035 |a (DE-He213)s40256-023-00596-3-e 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
082 0 4 |a 610  |q VZ 
084 |a 15,3  |2 ssgn 
084 |a PHARM  |q DE-84  |2 fid 
100 1 |a Xiong, Yilin  |e verfasserin  |4 aut 
245 1 0 |a Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 
520 |a Abstract Vascular smooth muscle cells (VSMCs) proliferation is a critical event that contributes to the pathogenesis of vascular remodeling such as hypertension, restenosis, and pulmonary hypertension. Increasing evidences have revealed that VSMCs proliferation is associated with the activation of receptor tyrosine kinases (RTKs) by their ligands, including the insulin-like growth factor receptor (IGFR), fibroblast growth factor receptor (FGFR), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR). Moreover, some receptor tyrosinase inhibitors (TKIs) have been found and can prevent VSMCs proliferation to attenuate vascular remodeling. Therefore, this review will describe recent research progress on the role of RTKs and their inhibitors in controlling VSMCs proliferation, which helps to better understand the function of VSMCs proliferation in cardiovascular events and is beneficial for the prevention and treatment of vascular disease. 
700 1 |a Wang, Yan  |4 aut 
700 1 |a Yang, Tao  |4 aut 
700 1 |a Luo, Yunmei  |4 aut 
700 1 |a Xu, Shangfu  |4 aut 
700 1 |a Li, Lisheng  |4 aut 
773 0 8 |i Enthalten in  |t American journal of cardiovascular drugs  |d Springer International Publishing, 2001  |g 23(2023), 5 vom: 31. Juli, Seite 497-518  |h Online-Ressource  |w (DE-627)327643943  |w (DE-600)2043647-6  |w (DE-576)39809991X  |x 1179-187X  |7 nnns 
773 1 8 |g volume:23  |g year:2023  |g number:5  |g day:31  |g month:07  |g pages:497-518 
856 4 0 |u https://dx.doi.org/10.1007/s40256-023-00596-3  |z lizenzpflichtig  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_OLC 
912 |a FID-PHARM 
912 |a SSG-OLC-PHA 
912 |a SSG-OPC-PHA 
912 |a SSG-OPC-DE-84 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_23 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_32 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_60 
912 |a GBV_ILN_62 
912 |a GBV_ILN_63 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_73 
912 |a GBV_ILN_74 
912 |a GBV_ILN_90 
912 |a GBV_ILN_95 
912 |a GBV_ILN_100 
912 |a GBV_ILN_101 
912 |a GBV_ILN_105 
912 |a GBV_ILN_110 
912 |a GBV_ILN_120 
912 |a GBV_ILN_138 
912 |a GBV_ILN_150 
912 |a GBV_ILN_151 
912 |a GBV_ILN_152 
912 |a GBV_ILN_161 
912 |a GBV_ILN_170 
912 |a GBV_ILN_171 
912 |a GBV_ILN_187 
912 |a GBV_ILN_213 
912 |a GBV_ILN_224 
912 |a GBV_ILN_230 
912 |a GBV_ILN_250 
912 |a GBV_ILN_266 
912 |a GBV_ILN_281 
912 |a GBV_ILN_285 
912 |a GBV_ILN_293 
912 |a GBV_ILN_370 
912 |a GBV_ILN_602 
912 |a GBV_ILN_636 
912 |a GBV_ILN_702 
912 |a GBV_ILN_2001 
912 |a GBV_ILN_2003 
912 |a GBV_ILN_2004 
912 |a GBV_ILN_2005 
912 |a GBV_ILN_2006 
912 |a GBV_ILN_2007 
912 |a GBV_ILN_2008 
912 |a GBV_ILN_2009 
912 |a GBV_ILN_2010 
912 |a GBV_ILN_2011 
912 |a GBV_ILN_2014 
912 |a GBV_ILN_2015 
912 |a GBV_ILN_2020 
912 |a GBV_ILN_2021 
912 |a GBV_ILN_2025 
912 |a GBV_ILN_2026 
912 |a GBV_ILN_2027 
912 |a GBV_ILN_2031 
912 |a GBV_ILN_2034 
912 |a GBV_ILN_2037 
912 |a GBV_ILN_2038 
912 |a GBV_ILN_2039 
912 |a GBV_ILN_2044 
912 |a GBV_ILN_2048 
912 |a GBV_ILN_2049 
912 |a GBV_ILN_2055 
912 |a GBV_ILN_2057 
912 |a GBV_ILN_2059 
912 |a GBV_ILN_2061 
912 |a GBV_ILN_2064 
912 |a GBV_ILN_2065 
912 |a GBV_ILN_2068 
912 |a GBV_ILN_2088 
912 |a GBV_ILN_2093 
912 |a GBV_ILN_2106 
912 |a GBV_ILN_2107 
912 |a GBV_ILN_2108 
912 |a GBV_ILN_2110 
912 |a GBV_ILN_2111 
912 |a GBV_ILN_2112 
912 |a GBV_ILN_2113 
912 |a GBV_ILN_2118 
912 |a GBV_ILN_2129 
912 |a GBV_ILN_2134 
912 |a GBV_ILN_2143 
912 |a GBV_ILN_2144 
912 |a GBV_ILN_2147 
912 |a GBV_ILN_2148 
912 |a GBV_ILN_2152 
912 |a GBV_ILN_2153 
912 |a GBV_ILN_2188 
912 |a GBV_ILN_2190 
912 |a GBV_ILN_2232 
912 |a GBV_ILN_2446 
912 |a GBV_ILN_2470 
912 |a GBV_ILN_2474 
912 |a GBV_ILN_2507 
912 |a GBV_ILN_2522 
912 |a GBV_ILN_2548 
912 |a GBV_ILN_4035 
912 |a GBV_ILN_4037 
912 |a GBV_ILN_4046 
912 |a GBV_ILN_4112 
912 |a GBV_ILN_4125 
912 |a GBV_ILN_4126 
912 |a GBV_ILN_4242 
912 |a GBV_ILN_4246 
912 |a GBV_ILN_4249 
912 |a GBV_ILN_4251 
912 |a GBV_ILN_4305 
912 |a GBV_ILN_4306 
912 |a GBV_ILN_4307 
912 |a GBV_ILN_4313 
912 |a GBV_ILN_4322 
912 |a GBV_ILN_4323 
912 |a GBV_ILN_4324 
912 |a GBV_ILN_4325 
912 |a GBV_ILN_4326 
912 |a GBV_ILN_4328 
912 |a GBV_ILN_4333 
912 |a GBV_ILN_4334 
912 |a GBV_ILN_4335 
912 |a GBV_ILN_4336 
912 |a GBV_ILN_4338 
912 |a GBV_ILN_4393 
912 |a GBV_ILN_4700 
951 |a AR 
952 |d 23  |j 2023  |e 5  |b 31  |c 07  |h 497-518